Last reviewed 2026-05-23 · How we verify

Entyvio (vedolizumab)

Entyvio (generic name: vedolizumab) is a Integrin Receptor Antagonist [EPC] drug developed by Takeda. It is currently FDA-approved for Chronic antibioticrefractory ileal pouchitis, Crohn's disease, Ulcerative colitis.

Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue.

Entyvio, also known as vedolizumab, is a monoclonal antibody medication that targets the integrin alpha-4/beta-7 to inhibit inflammation in the gut. It is used to treat conditions such as ulcerative colitis and Crohn's disease, which are forms of inflammatory bowel disease.

At a glance

Mechanism of action

Vedolizumab selectively targets the α4β7 integrin expressed on memory T-lymphocytes that preferentially home to the gastrointestinal tract. By blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells, it prevents the migration of these immune cells across the endothelium into inflamed gastrointestinal parenchymal tissue. This mechanism reduces chronic inflammation characteristic of ulcerative colitis and Crohn's disease. Notably, vedolizumab does not affect α4β1 or αEβ7 integrins, nor does it antagonize α4 integrin interactions with VCAM-1, providing gut-selective immunosuppression.

Approved indications

• Chronic antibioticrefractory ileal pouchitis
• Crohn's disease
• Ulcerative colitis

Common side effects

• Nasopharyngitis
• Headache
• Arthralgia
• Nausea
• Pyrexia
• Upper respiratory tract infection
• Fatigue
• Cough
• Bronchitis
• Influenza
• Back pain
• Rash

Serious adverse events

• Serious adverse reactions (overall)
• Anaphylaxis
• Serious infusion-related reactions
• Hypersensitivity reactions

Key clinical trials

• Evaluation of Effectiveness and Tolerance of Intravenous and Subcutaneous Biological Drugs in Gastrointestinal Diseases (BIOES) (N/A)
• Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease (N/A)
• IBD Cancer and Serious Infection in Europe (N/A)
• A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST) (Phase 4)
• Combining Biological Therapies in Patients With Inflammatory Bowel Disease: a Finnish Multi-centre Study. (N/A)
• Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission (Phase 2)
• Comparison of the PillCamCOLON (C2) Capsule With Standard Endoscopy for the Evaluation of the Severity and the Endoscopic Healing of Patients With Ulcerative Colitis (UC) (NA)
• Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Re (N/A)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Entyvio CI brief — competitive landscape report
• Entyvio updates RSS · CI watch RSS
• Takeda portfolio CI

Frequently asked questions about Entyvio

Related

• Drug class: All Integrin Receptor Antagonist [EPC] drugs
• Target: All drugs targeting Integrin alpha-4/beta-7
• Manufacturer: Takeda — full pipeline
• Therapeutic area: All drugs in Gastroenterology
• Indication: Drugs for Chronic antibioticrefractory ileal pouchitis
• Indication: Drugs for Crohn's disease
• Indication: Drugs for Ulcerative colitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing